TOPLINE:

A novel Comprehensive Health Assessment Risk Model (CHARM) incorporating seven health variables effectively predicts nonrelapse mortality and survival in allogeneic hematopoietic cell transplantation recipients aged at least 60 years. The model stratified 1-year nonrelapse mortality rates from 8.1% to 23.3% across risk groups, outperforming traditional assessment methods.

METHODOLOGY:

A multicenter (n = 49), prospective, observational clinical trial enrolled 1105 recipients of allogeneic hematopoietic cell transplantation aged ≥ 60 years (range, 60-82 years) from centers across the US.

Researchers analyzed associations between 13 measurements of older adult health and nonrelapse mortality within 1 year to construct a comprehensive health assessment risk model using multivariat

See Full Page